Enterprise Therapeutics announces that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has granted ETD001 designation as an orphan medicinal product for the treatment of cystic fibrosis.

This follows the announcement earlier this year of a positive Phase II clinical trial outcome of ETD0011, an investigational inhaled epithelial sodium channel (ENaC) blocker, designed to increase lung function by improving mucus clearance and reducing airway obstruction.
The EMA COMP opinion concluded that ETD001 meets the orphan-designation criteria, recognising disease rarity and the potential for ETD001 to provide clinically relevant benefit, including for people who are not eligible for CFTR modulator therapy.
The recommendation was supported by clinical data from the Phase II ET-ENAC-03 study, which were indicative of lung function improvement.
Orphan medicine designation offers a range of benefits, including market exclusivity once the therapy is on the market.
Dr John Ford (pictured above), CEO, Enterprise Therapeutics, commented: “Orphan drug designation represents an important regulatory milestone for the ETD001 programme and for Enterprise Therapeutics."
"The decision by the EMA reflects the continued need for additional treatment options for people with cystic fibrosis, particularly those who are not able to benefit from CFTR modulators. We look forward to continuing the development of ETD001 in CF as well as other mucus congestion-related respiratory diseases.”

Annabella Amatulli (pictured right), Head of Regulatory Affairs, Enterprise Therapeutics, added: “Our regulatory strategy supports our global development plan for ETD001, aligned with our goal to provide improved therapeutic options for people with cystic fibrosis."
"The EMA’s orphan drug designation further validates the strength of the programme’s scientific rationale and outcomes of the Phase II clinical trial.”
Cystic fibrosis is estimated to affect more than 100,000 people worldwide and leads to reduced life expectancy.
Failed mucociliary clearance and mucus congestion in the lungs lead to cycles of infection and inflammation and an ongoing decline in lung function.